Omeros gains a new head of commercial and a VP of CMC from Celgene, while Alimera Sciences promotes its president to CEO and Constellation Pharma moves its translational sciences head to CSO.

O'Day brings Gilead experience in oncology and M&A from a large, diversified organization.

Novartis India’s managing director has quit - the second time in 2018 that the Swiss multinational finds the corner office vacated.

Bayer adds new VPs in Government Relations and US Corporate Engagement from Monsanto. And at Janssen R&D, Global Head, Discovery Sciences moves to CSO position at Incyte Corp. Meanwhile, Axovant Sciences revamps its team. 

Ipsen VP, Endocrinology is now CSO at metabolic and rare disease Alize Pharma, and cancer and infectious disease firm Innovio Pharmaceuticals promotes R&D leader to CSO. Plus new Head, Oncology at Nektar Therapeutics to lead area strategy.

Immuno-oncology treatment developer Five Prime Therapeutics hires a CFO, while Myovant Sciences, focused on women’s health and endocrine disease, appoints a chief commercial officer. And Onconova Therapeutics boosts its drug development expertise with addition of new CMO, R&D.

Sosei Group selects a new EVP, CFO and Rare Diseases VP departs Shire for Blueprint Medicines. At Ferring Pharmaceuticals, COO makes known plans to step down.

Ferring announced this morning (Oct. 31) that Michel Pettigrew is retiring as president of the executive board and will be succeeded by CSO Per Falk. The two spoke to Scrip recently and outlined the Swiss-based firm's future strategy.

This week's company moves include a new CEO for Perrigo, while Harpoon Therapeutics and CardioVascular BioTherapeutics get new chief medical officers. And after seven years, the the chairman of BTG shares his decision to depart at end of year.